This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Apr 10;34(11):1282-3.

doi: 10.1200/JCO.2015.65.2438. Epub 2016 Feb 16.

Reply to T.J. Kruser et al

Affiliations

Affiliations

¹ Aix-Marseille University, AP-HM, Centre Hospitalier Universitaire Timone, Marseille, France olivier.chinot@ap-hm.fr.
² Medical Center Haaglanden, The Hague, and VU University Medical Center, Amsterdam, the Netherlands.
³ Genentech, South San Francisco, CA.
⁴ F. Hoffmann-La Roche, Basel, Switzerland.
⁵ University Medical Center, Heidelberg, Germany.
⁶ Princess Margaret Hospital, Toronto, Ontario, Canada.
⁷ Regional Cancer Center Stockholm, Stockholm, and Umeå University, Umeå, Sweden.
⁸ The Royal Marsden National Health Service Foundation Trust, Surrey, United Kingdom.
⁹ Saitama Medical University, Saitama, Japan.
¹⁰ University of California, Los Angeles, Los Angeles, CA.

PMID: 26884575
DOI: 10.1200/JCO.2015.65.2438

Comment

Reply to T.J. Kruser et al

Olivier L Chinot et al. J Clin Oncol. 2016.

. 2016 Apr 10;34(11):1282-3.

doi: 10.1200/JCO.2015.65.2438. Epub 2016 Feb 16.

Authors

Affiliations

¹ Aix-Marseille University, AP-HM, Centre Hospitalier Universitaire Timone, Marseille, France olivier.chinot@ap-hm.fr.
² Medical Center Haaglanden, The Hague, and VU University Medical Center, Amsterdam, the Netherlands.
³ Genentech, South San Francisco, CA.
⁴ F. Hoffmann-La Roche, Basel, Switzerland.
⁵ University Medical Center, Heidelberg, Germany.
⁶ Princess Margaret Hospital, Toronto, Ontario, Canada.
⁷ Regional Cancer Center Stockholm, Stockholm, and Umeå University, Umeå, Sweden.
⁸ The Royal Marsden National Health Service Foundation Trust, Surrey, United Kingdom.
⁹ Saitama Medical University, Saitama, Japan.
¹⁰ University of California, Los Angeles, Los Angeles, CA.

PMID: 26884575
DOI: 10.1200/JCO.2015.65.2438

No abstract available

PubMed Disclaimer

Comment on

Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, Saran F, Nishikawa R, Hilton M, Theodore-Oklota C, Ravelo A, Chinot OL. Taphoorn MJ, et al. J Clin Oncol. 2015 Jul 1;33(19):2166-75. doi: 10.1200/JCO.2014.60.3217. Epub 2015 May 26. J Clin Oncol. 2015. PMID: 26014298 Clinical Trial.
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C. Sandmann T, et al. J Clin Oncol. 2015 Sep 1;33(25):2735-44. doi: 10.1200/JCO.2015.61.5005. Epub 2015 Jun 29. J Clin Oncol. 2015. PMID: 26124478 Free PMC article.
Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient?
Kruser TJ, Mehta MP, Kozak KR. Kruser TJ, et al. J Clin Oncol. 2016 Apr 10;34(11):1281-2. doi: 10.1200/JCO.2015.64.7883. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884565 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information